Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-Matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies
作者单位:Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke[1]Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, United[2]